Gilles Montalescot

Summary

Country: France

Publications

  1. ncbi Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
    Jean Philippe Collet
    Institut de Cardiologie, , Paris, France
    J Am Coll Cardiol 41:8-14. 2003
  2. ncbi Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France Electronic address
    Am Heart J 165:515-22. 2013
  3. ncbi Current antiplatelet options for NSTE-ACS patients
    G Cayla
    Institut de Cardiologie, bureau 236, Pitie Salpetriere University Hospital, 47 83, bld de l Hôpital, 75013 Paris, France
    QJM 105:935-48. 2012
  4. ncbi Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells
    Seraya Maouche
    INSERM UMR S525, Faculte de Medecine Pierre et Marie Curie, Universite Paris VI, 91 Boulevard de l Hopital, Paris 75634 Cedex 13, France
    BMC Genomics 9:302. 2008
  5. ncbi Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, AP HP, and INSERM Unit 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Int J Cardiol 150:79-83. 2011
  6. ncbi Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    JAMA 302:947-54. 2009
  7. ncbi A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Gilles Montalescot
    Institut de Cardiologie Pitié Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris APHP, Paris, France
    J Am Coll Cardiol 48:931-8. 2006
  8. ncbi Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
  9. ncbi Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
  10. ncbi A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study
    Gilles Montalescot
    Hopital de la Pitie Salpetriere, Paris, France
    Am Heart J 161:650-656.e1. 2011

Detail Information

Publications120 found, 100 shown here

  1. ncbi Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
    Jean Philippe Collet
    Institut de Cardiologie, , Paris, France
    J Am Coll Cardiol 41:8-14. 2003
    ..In these patients, enoxaparin with dose adjustment to creatinine clearance provides adequate anti-Xa levels and no excess of bleeding...
  2. ncbi Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France Electronic address
    Am Heart J 165:515-22. 2013
    ..The primary safety end point is major, life-threatening, or minor bleeding after ticagrelor administration. The results of this study may have an impact on future recommendations for treatment for patients with STEMI...
  3. ncbi Current antiplatelet options for NSTE-ACS patients
    G Cayla
    Institut de Cardiologie, bureau 236, Pitie Salpetriere University Hospital, 47 83, bld de l Hôpital, 75013 Paris, France
    QJM 105:935-48. 2012
    ....
  4. ncbi Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells
    Seraya Maouche
    INSERM UMR S525, Faculte de Medecine Pierre et Marie Curie, Universite Paris VI, 91 Boulevard de l Hopital, Paris 75634 Cedex 13, France
    BMC Genomics 9:302. 2008
    ..In addition, a reference list of differentially expressed genes (DEG) was generated from a larger number of hybridizations (mRNA from 86 individuals) using the RNG/MRC two-color platform...
  5. ncbi Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, AP HP, and INSERM Unit 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Int J Cardiol 150:79-83. 2011
    ....
  6. ncbi Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    JAMA 302:947-54. 2009
    ..International guidelines recommend an early invasive strategy for patients with high-risk acute coronary syndromes without ST-segment elevation, but the optimal timing of intervention is uncertain...
  7. ncbi A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Gilles Montalescot
    Institut de Cardiologie Pitié Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris APHP, Paris, France
    J Am Coll Cardiol 48:931-8. 2006
    ..We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs)...
  8. ncbi Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
    ..We compared traditional heparin treatment with intravenous enoxaparin in primary PCI...
  9. ncbi Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
    ..Our purpose was to evaluate long-term mortality and identify factors associated with 1-year mortality in patients who underwent elective percutaneous coronary intervention (PCI)...
  10. ncbi A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study
    Gilles Montalescot
    Hopital de la Pitie Salpetriere, Paris, France
    Am Heart J 161:650-656.e1. 2011
    ..Prasugrel, a novel thienopyridine, is an appropriate drug to address this issue as it provides predictably high and rapid inhibition of platelet aggregation...
  11. ncbi Platelet biology and implications for antiplatelet therapy in atherothrombotic disease
    Gilles Montalescot
    Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Clin Appl Thromb Hemost 17:371-80. 2011
    ..We expect that this new approach may mitigate bleeding risk, because PAR-1 is not essential for hemostasis...
  12. ncbi Mechanical reperfusion: treat well, treat on time too
    Gilles Montalescot
    INSERM U 856, Institut de Cardiologie, , , Paris 75013, France
    Lancet 372:509-10. 2008
  13. ncbi STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
    Gilles Montalescot
    Institut de Cardiologie and INSERM U856, Pitie Salpetriere University Hospital, AP HP, 47 Boulevard de l Hopital, Paris 75013, France
    Eur Heart J 28:1409-17. 2007
    ..The aim of this study was to describe the management and outcomes using 'real-world' data taking the new definition of acute myocardial infarction into account...
  14. ncbi Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  15. ncbi Unprotected left main revascularization in patients with acute coronary syndromes
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Blvd de l Hopital, 75013 Paris, France
    Eur Heart J 30:2308-17. 2009
    ....
  16. ncbi Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up
    Gilles Montalescot
    Institute of Cardiology APHP and INSERM unit 856, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 28:443-9. 2007
    ..We performed a meta-analysis on case specific data of primary stenting in STEMI with a long-term evaluation...
  17. ncbi Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study
    Gilles Montalescot
    Institut de Cardiologie AP HP, INSERM U856 and Universite Paris 6, Hopital Pitie Salpetriere, Paris, France
    Thromb Haemost 103:213-23. 2010
    ..Thus, in ACS patients a prasugrel 10-mg MD regimen resulted in significantly greater platelet inhibition than clopidogrel at twice its approved MD or a 900-mg LD...
  18. ncbi Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  19. ncbi Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM U856 and University of Paris 6, Pitie Salpetriere Hospital, Paris, France
    Am J Cardiol 104:904-9. 2009
    ..In conclusion, high hospital levels of CITP, a marker of collagen degradation and ventricular remodeling, are associated with late mortality and other serious clinical events after AMI...
  20. ncbi Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM U937 and Univ Paris 6, Pitie Salpetriere Hospital, Paris, France
    Catheter Cardiovasc Interv 79:104-12. 2012
    ..We evaluated the incidence, types, and prognostic impact of bleeding complications in a non-selected patient population with ongoing STEMI treated with aggressive antithrombotic treatment and routine radial primary PCI...
  21. ncbi High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
    Jean Philippe Collet
    Institut de Cardiologie, INSERM CMR937, Hôpital Pitié Salpêtrière Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie UPMC, Paris VI, Paris, France
    JACC Cardiovasc Interv 4:392-402. 2011
    ..This study sought to determine whether the pharmacokinetic (PK) and pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) differ according to CYP2C19*2 allele...
  22. ncbi Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE)
    Gilles Montalescot
    Service de cardiologie, Pitie Salpetriere Hospital, Paris, France
    Catheter Cardiovasc Interv 60:360-7. 2003
    ..4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%)...
  23. ncbi Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
    Miles Dalby
    Institut de Cardiologie, , Paris, France
    J Am Coll Cardiol 43:162-8. 2004
    ..The P2 and P-selectin findings suggest the possibility of a partial agonist and/or pro-inflammatory effect...
  24. ncbi Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates
    Farzin Beygui
    Department of Cardiology and INSERM, Pitié Salpêtrière University Hospital APHP, Paris, France
    Am J Cardiol 106:650-8. 2010
    ..In low-risk populations, a strategy using these biomarkers might help in identifying patients at greater risk of additional events...
  25. ncbi One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent
    Olivier Barthelemy
    Centre Hospitalier Universitaire Pitie Salpetriere, AP HP, Institut de Cardiologie, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 104:604-10. 2011
    ..It is unknown whether the efficacy and safety of drug-eluting stents (DES) apply in patients with chronic renal failure (CRF)...
  26. ncbi FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype--phenotype case control study
    Johanne Silvain
    Institut de Cardiologie, INSERM UMRS 937, Pitie Salpetriere Hospital, AP HP, Universite Paris 6, Paris, France
    Thromb Haemost 106:511-20. 2011
    ..01). In conclusion, FXIII-A Leu34 is a polymorphism which provides a strong resistance to fibrinolysis with a gene-dose effect, but does not relate to premature CAD or to recurrent coronary events in this study...
  27. ncbi Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    Jean Philippe Collet
    Institut de Cardiologie Hôpital Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    N Engl J Med 367:2100-9. 2012
    ..Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy...
  28. ncbi Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study
    Anne Bellemain-Appaix
    Institut de Cardiologie INSERM 937, Pitie Salpetriere University Hospital, APHP, Paris, France
    Catheter Cardiovasc Interv 79:823-33. 2012
    ..We sought to compare physical and morphological properties of fibrin clots made in the presence of ioxaglate (ICM), iodixanol (NICM) versus control and to evaluate the effect of four anticoagulants used in PCI...
  29. ncbi High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
    Johanne Silvain
    bureau 236, Institut de Cardiologie, INSERM UMRS937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, 47 83 boulevard de l Hopital, Paris, France
    Eur Heart J 33:1241-9. 2012
    ..younger patients (<75 years). Elderly patients represent a growing and challenging segment of the coronary population for whom the effect of dual antiplatelet therapy on platelet inhibition has not been specifically addressed...
  30. ncbi CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    Jean Sebastien Hulot
    Universite Pierre et Marie Curie Paris 6, INSERM UMR S 956, Pharmacology Department, Pitie Salpetriere University Hospital, Paris, France
    Circ Cardiovasc Interv 4:422-8. 2011
    ..We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics and the occurrence of cardiovascular outcomes in young post-myocardial infarction (MI) patients treated with clopidogrel...
  31. ncbi [Myocardial infarction: Role of new antiplatelet agents]
    Johanne Silvain
    Universite Paris 6, Institut de Cardiologie, INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Paris, France
    Presse Med 40:615-24. 2011
    ..e. in the elderly patient with comorbidities...
  32. ncbi Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
    Johanne Silvain
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    BMJ 344:e553. 2012
    ..To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention...
  33. ncbi Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
    Jean Sebastien Hulot
    Pharmacology Department, Institute of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Clin Pharmacol Ther 77:542-52. 2005
    ..However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment...
  34. ncbi Real-life management of dual antiplatelet therapy interruption: the REGINA survey
    Jean Philippe Collet
    bureau 236, Inserm 937, Institut de Cardiologie, hôpital Pitié Salpêtrière AP HP, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:697-710. 2009
    ..The nationwide REGINA survey was designed to evaluate how the interruption of dual APT is managed in the 'real world'...
  35. ncbi Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
    Jean Sebastien Hulot
    Service de Pharmacologie, Unité de Pharmacogénétique, INSERM UMRS 956, Hopital Pitie Salpetriere, Paris, France
    J Am Coll Cardiol 56:134-43. 2010
    ....
  36. ncbi Platelet function testing and implications for clinical practice
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    J Cardiovasc Pharmacol Ther 14:157-69. 2009
    ....
  37. ncbi Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
    Guillaume Cayla
    Institut de Cardiologie, INSERM Unité Mixte de Recherche_S 937, Pitie Salpetriere Hospital, Paris, France
    JAMA 306:1765-74. 2011
    ..Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI)...
  38. ncbi Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test
    Johanne Silvain
    Institut de Cardiologie, Institut National de la Santé et de la Recherche Médicale INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    J Am Coll Cardiol 55:617-25. 2010
    ..This study evaluated the ability of the bedside test Hemochron Jr. Hemonox (International Technidyne Corporation, Edison, New Jersey) to identify patients with insufficient anti-Xa activity level in the catheterization laboratory...
  39. ncbi Slow response to clopidogrel predicts low response
    Anne Bellemain-Appaix
    Assistance Publique Hopitaux de Paris, Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    J Am Coll Cardiol 55:815-22. 2010
    ..The purpose of this study was to determine whether the speed of response to clopidogrel loading predicts the final degree of response...
  40. ncbi Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials
    Raphaelle Dumaine
    Centre Hospitalier Universitaire Pitie Salpetriere, Institute of Cardiology, Bureau 2 236, 47 Blvd de l Hopital, 75013, Paris, France
    Arch Intern Med 167:2423-30. 2007
    ..Our objective was to perform a meta-analysis of randomized trials comparing the efficacy and safety of LMWH vs UFH as anticoagulants in the setting of PCI...
  41. ncbi Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
    Jean Philippe Collet
    Inserm unit 937, Institut de Cardiologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, bureau 236, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:485-96. 2009
    ..Late discontinuation of clopidogrel after an acute coronary syndrome or stent placement may be associated with a clinical rebound effect...
  42. ncbi Composition of coronary thrombus in acute myocardial infarction
    Johanne Silvain
    Institut de Cardiologie, INSERM UMRS937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    J Am Coll Cardiol 57:1359-67. 2011
    ..We sought to analyze the composition of coronary thrombus in vivo in ST-segment elevation myocardial infarction (STEMI) patients...
  43. ncbi Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    Jean Philippe Collet
    Institut de Cardiologie, INSERM 856, Universite Paris 6, hôpital Pitié Salpêtrière AP HP, Paris, France
    Lancet 373:309-17. 2009
    ..We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel...
  44. ncbi Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans o
    Farzin Beygui
    Institut de Cardiologie and INSERM U, Pitie Salpetriere University Hospital, APHP, Paris, France
    Am Heart J 157:680-7. 2009
    ..Whether there is a relationship between aldosterone levels and outcome in a broader spectrum of patients admitted for AMI defined by the new definition based on troponin levels remains unknown...
  45. ncbi Antiplatelet options for secondary prevention in acute coronary syndromes
    Johanne Silvain
    INSERM UMRS 937, Pitie Salpetriere Hospital, Institut de Cardiologie, University Paris, Paris 6, France
    Expert Rev Cardiovasc Ther 9:1403-15. 2011
    ..Despite an increase in bleeding risk, prasugrel and ticagrelor appear to have a better net clinical benefit, especially in higher-risk patients with ACS...
  46. ncbi Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Groupe Hospitalier Pitié Salpêtrière Hospital, AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    Am J Cardiol 91:925-30. 2003
    ..vWF and its receptor glycoprotein Ib/IX play a key role in acute coronary syndromes. vWF is linked to inflammation and, like glycoprotein Ib/IX, is affected more favorably by the LWMHs than by UFH...
  47. ncbi Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis
    Paola Sanchez-Pena
    Pharmacology Department, Pitie-Salpetriere University Hospital, Assistance-Publique Hospitaux de Paris, Paris 6 University, Paris, France
    Br J Clin Pharmacol 60:364-73. 2005
    ..An additional second bolus could be proposed in patients with delayed or prolonged procedures...
  48. ncbi [Anti-thrombotic therapy of acute coronary syndromes without ST elevation]
    Gilles Montalescot
    Institut de Cardiologie, Groupe Hospitalier Pitie Salpetriere, AP HP, 47, Boulevard de l Hopital, 75013 Paris
    Bull Acad Natl Med 189:217-25; discussion 225-6. 2005
    ..Combined antithrombotic therapy also increases the benefit of early invasive strategies including coronary angiogram with stent-based percutaneous coronary angioplasty...
  49. ncbi A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
    Remi Choussat
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    J Am Coll Cardiol 40:1943-50. 2002
    ....
  50. ncbi Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
    Ziad Mallat
    Institut National de la Santé et la Recherche Médicale, INSERM U541, Institut Fédératif de Recherche IRF Circulation, Paris, France
    J Am Coll Cardiol 46:1249-57. 2005
    ..The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS)...
  51. ncbi Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis
    Maria Borentain
    Institut de Cardiologie, , Paris, France
    Catheter Cardiovasc Interv 65:212-21. 2005
    ..During PCI, intravenous LMWH without coagulation monitoring has the potential to be at least as safe and efficacious as intravenous UFH. Further studies of LMWHs in PCI are therefore required...
  52. ncbi Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study
    Jean Philippe Collet
    Institut de Cardiologie, Unité INSERM 856, Pitié Salpêtrière University Hospital AP HP, Paris, France
    Circulation 118:1225-33. 2008
    ....
  53. ncbi Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study
    Johanne Silvain
    Institut de Cardiologie, Bureau 2 236, INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, 47 83 bld de l Hôpital, 75013 Paris, France
    Eur Heart J 31:2816-21. 2010
    ..The aim of this paper is to determine whether RBC transfusion increases platelet activation and aggregation...
  54. ncbi Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
    Jean-Philippe Collet
    Department of Cardiology, , Bureau 2-236, 47, , 75013 Paris, France
    Eur Heart J 26:2285-93. 2005
    ..Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors...
  55. ncbi Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference
    Farzin Beygui
    Department of Cardiology, , Paris, France
    Circulation 113:e21-3. 2006
  56. ncbi Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    Gilles Montalescot
    Institute of Cardiology, INSERM U856, Universite Paris 6, Pitié Salpêtrière Hospital AP HP, Paris, France
    Lancet 373:723-31. 2009
    ..Prasugrel, a potent and rapid-acting thienopyridine, is a potential alternative to clopidogrel. We aimed to assess prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) for STEMI...
  57. ncbi New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis
    Anne Bellemain-Appaix
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    J Am Coll Cardiol 56:1542-51. 2010
    ..The purpose of this study was to perform a meta-analysis of randomized trials that compare new P2Y(12) inhibitors with clopidogrel to determine whether they improve clinical outcomes after percutaneous intervention (PCI)...
  58. ncbi Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM CMR937 and Univ Paris 6, Pitie Salpetriere Hospital, Paris, France
    Int J Cardiol 163:266-71. 2013
    ..We aimed to assess whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular (CV) events in stable patients with established atherothrombosis or multiple risk factors...
  59. ncbi Prasugrel monitoring and bleeding in real world patients
    Guillaume Cayla
    Institut de Cardiologie, INSERM UMRS937, Pitie Salpetriere Hospital, Universite Paris 6, Paris, France
    Am J Cardiol 111:38-44. 2013
    ..Minor or minimal bleeding is frequent, but not major bleeding. VASP was poorly correlated with the risk for minor or minimal bleeding...
  60. ncbi Feasibility of outpatient coronary angiography with "ad hoc" angioplasty
    Arnaud Chaumeil
    Institute of Cardiology, Pitié Salpêtrière Hospital Group, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Arch Cardiovasc Dis 101:383-90. 2008
    ..It combines the advantages of increased convenience for the patient and lower costs...
  61. ncbi [Platelet aggregation and antiplatelet agents in acute coronary syndromes]
    Jean Philippe Collet
    Institut de Cardiologie, Hopital de la Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Sci (Paris) 20:291-7. 2004
    ..Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients...
  62. ncbi Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial
    Farzin Beygui
    Institut de Cardiologie and INSERM U937, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Am Heart J 160:642-8. 2010
    ..Angiotensin-converting enzyme inhibitors have delayed partial and temporary effects on aldosterone levels. We hypothesize that aldosterone receptor blockade, early after AMI onset on top of standard therapy, may improve clinical outcome...
  63. ncbi Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin
    Alexandre Ouattara
    Department of Anaesthesiology and Critical Care, Institute of Cardiology, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Université Pierre et Marie Curie Paris, Paris, France
    Eur Heart J 28:1025-32. 2007
    ....
  64. ncbi Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)
    Gilles Montalescot
    Pitie Salpetriere University Hospital, Paris, France
    JACC Cardiovasc Interv 3:203-12. 2010
    ..The aim of this study was to assess the risk-benefit of enoxaparin (Sanofi-Aventis, Paris, France) in primary percutaneous coronary intervention (PCI)...
  65. ncbi Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe
    Patrice P Cacoub
    AP HP Service de Médecine Interne, Groupe Hospitalier La Pitié Salpêtrière, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Heart 97:660-7. 2011
    ..To examine the impact of cardiovascular risk factor control on 3-year cardiovascular event rates in patients with stable symptomatic atherothrombotic disease in Europe...
  66. ncbi Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease
    Farzin Beygui
    Cardiology Department, Pitie Salpetriere University Hospital, Paris, France
    J Heart Lung Transplant 29:316-22. 2010
    ..We aimed to assess the outcome of successful PCI with BMS or drug-eluting stenting (DES) in such patients...
  67. ncbi Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy
    Jean-Philippe Collet
    , Paris, France
    J Am Coll Cardiol 48:1326-35. 2006
    ..30; 95% CI, 0.92 to 1.83; p = 0.13). CONCLUSIONS: Our findings support rescue PCI and systematic and early PCI after fibrinolysis. However, the current data do not support fibrinolysis-facilitated PCI in lieu of primary PCI alone...
  68. ncbi Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment
    Jean Sebastien Hulot
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ther Drug Monit 26:305-10. 2004
    ....
  69. ncbi The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
    Jean-Philippe Collet
    Institut de Cardiologie, , , 75013 Paris, France
    Diab Vasc Dis Res 2:136-43. 2005
    ..This review examines all these important issues...
  70. ncbi Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
    Jean Philippe Collet
    Institut de Cardiologie, Hopital Pitie Salpetriere, Paris, France
    Am Heart J 161:5-12.e5. 2011
    ..Time and consequence of discontinuation of thienopyridine after stenting is also an unsolved issue after drug eluting stent (DES) implantation...
  71. ncbi Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay
    Patrick Ecollan
    SAMU, Pitie Salpetriere University Hospital, Paris, France
    Int J Cardiol 119:349-54. 2007
    ..To evaluate the diagnostic performance of a portable semi-quantitative whole blood immunoassay measuring soluble human fatty acid-binding protein [H-FABP] (CardioDetect) for the pre-hospital detection of myocardial infarction (MI)...
  72. ncbi Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational global registry of acute coronary events
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié Salptrière, Paris, France
    Am J Cardiol 95:1397-403. 2005
    ....
  73. ncbi Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis
    Gilles Montalescot
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    JAMA 292:362-6. 2004
    ..No systematic reviews have comprehensively examined the effects of early vs delayed administration of these agents...
  74. ncbi The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis
    Jean-Philippe Collet
    Institut de Cardiologie, , , France
    Blood 106:3824-30. 2005
    ..In conclusion, these studies provide the first definitive evidence that the alphaC domains play an important role in determining the structure and biophysical properties of clots and their susceptibility to fibrinolysis...
  75. ncbi Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
    Patrice P Cacoub
    Pierre and Marie Curie University Paris 6, and AP HP, Hospital La Pitié Salpêtrière, Paris, France
    Atherosclerosis 204:e86-92. 2009
    ..To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates...
  76. ncbi High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction
    Farzin Beygui
    Cardiology Department and INSERM U 856, , Paris, France
    Circulation 114:2604-10. 2006
    ..Such results underline the pivotal role of aldosterone and justify a randomized trial to assess the early administration of aldosterone antagonists in the setting of STEMI...
  77. ncbi Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
    Gilles Montalescot
    Bureau 2 236, Institut de Cardiologie, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
    Eur Heart J 30:2733-41. 2009
    ..This study investigated the effects of irbesartan vs. enalapril, with early vs. late treatment, on markers of inflammation and ischaemic heart disease in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS)...
  78. ncbi Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis
    Claude Le Feuvre
    Cardiology Department, Pitie Salpetriere Hospital, Paris, France
    Int J Cardiol 109:207-12. 2006
    ..This study aimed to assess the clinical outcome and to analyse predictive factors of cardiac events in patients with in-stent restenosis treated with Sirolimus-eluting stent (SES)...
  79. ncbi Images in cardiovascular medicine. Recurrent myocardial infarction in a patient with paroxysmal nocturnal hemoglobinuria
    Fabien Hyafil
    Institute of Cardiology, , Paris, France
    Circulation 108:e91-2. 2003
  80. ncbi Defining standards of care for facilitated and direct percutaneous coronary intervention
    Gilles Montalescot
    Division of Cardiology, Hĵpital la Pitié Salpétrière, Institut de Cardialogie, Paris, France
    Clin Cardiol 25:I27-32. 2002
    ..Since direct PCI is often a slow process, better use of existing and future therapies, as well as advances in patient transport, are expected to improve patient outcomes...
  81. ncbi Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events
    Ph Gabriel Steg
    INSERM U 698 Recherche Clinique en Athérothrombose, université Paris VII Denis Diderot, Assistance Publique Hopitaux de Paris, Centre Hospitalier Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    Eur Heart J 30:321-9. 2009
    ..To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI)...
  82. ncbi Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants
    Gilles Montalescot
    Institut de Cardiogie, Centre Hospitalier Universitarie Pitié Salpetrèire, Paris, France
    Clin Appl Thromb Hemost 15:183-96. 2009
    ..Future trials should report the rates of periprocedural complications when assessing the safety of novel anticoagulation therapies in PCI...
  83. ncbi Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
    Jean Philippe Collet
    Inserm 856 and Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    Int J Cardiol 133:8-17. 2009
    ..g. those who require non-cardiac surgery). This review discusses the benefits and risks of long-term dual antiplatelet therapy in a range of clinical situations...
  84. ncbi Myocardial infarction after endomyocardial biopsy in a heart transplant patient
    Gerard Drobinski
    Department of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    J Interv Cardiol 15:403-5. 2002
    ....
  85. ncbi Does preoperative coronary angioplasty improve perioperative cardiac outcome?
    Gilles Godet
    Anesthesiology and Critical Care, Hospitalo Universitaire Pitié Salpêtrière, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Anesthesiology 102:739-46. 2005
    ..However, the impact of this approach on postoperative outcome remains controversial...
  86. ncbi [New antiplatelet drugs]
    Anne Bellemain
    Institut de Cardiologie, Unité INSERM 856, Hôpital Pitié Salpêtrière F 75013 Paris, France
    Presse Med 37:1055-68. 2008
    ..But only very recently have new targets been developed. The synergy of their mechanisms of action now makes it possible to obtain ever stronger inhibition of platelet aggregation...
  87. ncbi Renal function, atherothrombosis extent, and outcomes in high-risk patients
    Raphaelle L Dumaine
    Pitie Salpetriere University Hospital, Paris, France
    Am Heart J 158:141-148.e1. 2009
    ..Although prior data showed an association between chronic kidney disease (CKD) and atherothrombotic events, little is known about the risk profile and specific outcomes of atherothrombotic outpatients with CKD...
  88. ncbi Multimodality imaging of percutaneous closure of the left atrial appendage
    Farzin Beygui
    Department of Cardiology, Institut de Cardiologie, , , 75013 Paris, France
    Eur Heart J 27:640. 2006
  89. ncbi Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    J Biol Chem 278:21331-5. 2003
    ....
  90. ncbi Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study)
    Raphaelle Dumaine
    Pitie Salpetriere Hospital, Paris, France
    Am J Cardiol 94:1543-7. 2004
    ..One third of patients with ACS presented with renal insufficiency. After adjustment for potential confounders, decreasing renal function was independently associated with in-hospital death, bleeding, and contrast-induced nephropathy...
  91. ncbi Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
    Dean J Kereiakes
    Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 144:615-24. 2002
    ....
  92. ncbi Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study
    Marc S Sabatine
    The Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 294:1224-32. 2005
    ..The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted...
  93. ncbi Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction
    Kurt Huber
    3rd Medical Department (Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A-1160 Vienna, Austria
    Eur Heart J 26:2063-74. 2005
  94. ncbi The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...
  95. ncbi Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  96. ncbi Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1179-89. 2005
    ....
  97. ncbi Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE)
    Alvaro Avezum
    Dante Pazzanese Cardiology Institute, Research Division, Sao Paulo, Brazil
    Am Heart J 149:67-73. 2005
    ..Evidence-based cardiac therapies are underutilized in elderly patients. We assessed differences in practice patterns, comorbidities, and in-hospital event rates, by age and type of acute coronary syndrome (ACS)...
  98. ncbi Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial
    Stephen G Ellis
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 147:E16. 2004
    ..We hypothesize that a strategy of early pharmacologic reperfusion therapy with abciximab alone or in conjunction with reduced-dose reteplase, followed by PCI will improve the outcome of patients eligible for primary PCI...
  99. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)...
  100. ncbi A preferred reperfusion strategy for acute myocardial infarction
    Eric J Topol
    J Am Coll Cardiol 42:1886-9. 2003
  101. ncbi [Medical treatment of acute coronary syndrome without ST-segment elevation]
    Jean Philippe Collet
    Institut de cardiologie Groupe hospitalier La Pitié La Salpêtrière 75651 Paris
    Rev Prat 53:624-8. 2003
    ..This combined antithrombotic also allowed to increase the benefit of an early invasive strategy including coronary angiogram with stent percutaneous coronary angioplasty...